CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kun Run Biotechnology, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kun Run Biotechnology, Inc.
243 Cranfield Green Se
Phone: (403) 370-1176p:403 370-1176 CALGARY, AB  T3M 1C4  Canada
This company ceased filing statements with the SEC on 12/10/2010.
This company is no longer actively traded on any major stock exchange.
Business Summary
Kun Run Biotechnology, Inc. is engaged, through Hainan Zhonghe Pharmaceutical Co., Ltd. (Zhonghe), its China-based indirect subsidiary, in the development, manufacture, marketing and sale of prescription polypeptide drugs. The Company’s principal products are prescription polypeptide drugs used to treat immune system malfunction and hyper function. Using various formulas, it produces a number of peptide products with several forms of delivery, including injections, capsules and pills. It manufactures and markets four polypeptide products across China: Thymopentin (TP-5), Somatostatin (SS),Thymosin Alpha 1 (Alpha 1) and Desmopressin Acetate (DDAVP).
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201012/31/2009YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
0200 Agricultural production-livestock and animal specialties

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board XueyunCui 51 9/16/2008 9/16/2008
Chief Executive Officer XiaoqunYe 45 9/16/2008 9/16/2008
Chief Accounting Officer YanLin 40 9/16/2008 9/16/2008

Subsidiaries
Business Name Address City State/Province Country
Hainan Zhonghe Pharmaceutical Co Ltd China

Business Names
Business Name
Aspen Racing Stables, Inc.
Hainan Zhonghe Pharmaceutical Co., Ltd.
Kun Run Biotechnology Ltd.
Kun Run Biotechnology, Inc.
KURU

General Information
Number of Employees: 149 (As of 12/31/2009)
Outstanding Shares: 25,000,000 (As of 11/19/2010)
Shareholders: 13
Stock Exchange: OTC
Federal Tax Id: 980517550


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023